Viridian Therapeutics Ors Inc (VRDN) is trading down at $22.82 (-0.83%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.48M | $4.00M | $8.39M | $4.46M | $1.05M | $2.96M | $1.77M | $314.0K | $302.0K | $70.8M |
| Growth (year over year) | −39.1% | +15.1% | +109.5% | −46.8% | −76.5% | +182.2% | −40.2% | −82.3% | −3.8% | +23359.9% |
| Gross profit | $929.0K | — | — | — | — | — | — | — | — | — |
| Gross margin | 26.7% | — | — | — | — | — | — | — | — | — |
| Operating income | −$17.0M | −$26.5M | −$33.1M | −$42.0M | −$110.4M | −$79.7M | −$134.3M | −$254.4M | −$299.0M | −$363.4M |
| Operating margin | −488.6% | −662.8% | −394.5% | −941.0% | −10512.4% | −2690.8% | −7579.2% | −81035.0% | −99018.2% | −512.9% |
| Net income | −$17.3M | −$26.5M | −$32.7M | −$41.9M | −$110.7M | −$79.4M | −$129.9M | −$237.7M | −$269.9M | −$342.6M |
| Net margin | −496.8% | −662.3% | −390.0% | −938.6% | −10544.3% | −2680.2% | −7329.2% | −75711.5% | −89387.1% | −483.6% |
| EPS (diluted) | −$6347.25 | −$310.50 | −$247.50 | −$20.04 | −$31.13 | −$6.66 | −$4.05 | −$5.31 | — | — |
| Balance sheet | ||||||||||
| Cash and equivalents | $22.1M | $47.4M | $32.6M | $24.8M | $45.9M | $42.3M | $155.6M | $102.8M | $99.6M | $212.4M |
| Total assets | $24.8M | $52.5M | $66.1M | $30.3M | $131.3M | $203.7M | $435.1M | $490.4M | $742.4M | $899.4M |
| Total liabilities | $9.71M | $14.0M | $14.8M | $14.5M | $11.2M | $16.0M | $40.0M | $48.4M | $70.8M | $177.3M |
| Long-term debt | — | $10.0M | $10.0M | $7.67M | — | $0 | $4.64M | $20.2M | $20.6M | — |
| Shareholders' equity | −$61.9M | $38.5M | $51.3M | $15.8M | $120.0M | $187.7M | $395.1M | $442.0M | $671.6M | $722.2M |
| Cash flow | ||||||||||
| Operating cash flow | −$14.8M | −$28.2M | −$26.8M | −$36.1M | −$29.8M | −$54.6M | −$93.8M | −$184.2M | −$232.3M | −$276.4M |
| Capital expenditure | $250.0K | $246.0K | $445.0K | $84.0K | $42.0K | $338.0K | $797.0K | $898.0K | $511.0K | $495.0K |
| Free cash flow | −$15.0M | −$28.4M | −$27.3M | −$36.1M | −$29.8M | −$54.9M | −$94.6M | −$185.1M | −$232.8M | −$276.9M |
| Share buybacks | $2.00K | — | — | — | — | — | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $86.0K | $72.0K | $72.0K | $75.0K | $70.6M | — | $141.0K | $284.0K |
| Growth (year over year) | +19.4% | 0.0% | 0.0% | +4.2% | +81958.1% | — | +95.8% | +278.7% |
| Operating income | −$83.5M | −$87.5M | −$93.9M | −$106.8M | −$40.0M | — | −$116.2M | −$126.3M |
| Operating margin | −97069.8% | −121487.5% | −130369.4% | −142356.0% | −56.7% | — | −82389.4% | −44460.6% |
| Net income | −$76.7M | −$79.7M | −$86.9M | −$100.7M | −$34.6M | — | −$104.9M | −$127.1M |
| Net margin | −89173.3% | −110729.2% | −120711.1% | −134313.3% | −49.0% | — | −74397.9% | −44760.2% |
| EPS (diluted) | −$1.15 | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash and equivalents | $200.3M | $99.6M | $116.2M | $117.3M | $169.6M | $212.4M | $176.3M | $165.0M |
| Total assets | $771.9M | $742.4M | $661.0M | $582.3M | $577.1M | $899.4M | $789.0M | $1.10B |
| Total liabilities | $64.4M | $70.8M | $56.5M | $67.2M | $74.2M | $177.3M | $153.0M | $435.1M |
| Long-term debt | $20.5M | $20.6M | $20.7M | $12.4M | $20.9M | — | — | — |
| Shareholders' equity | $707.5M | $671.6M | $604.5M | $515.2M | $503.0M | $722.2M | $636.0M | $662.1M |
| Cash flow | ||||||||
| Operating cash flow | −$67.7M | −$73.3M | −$92.7M | −$75.4M | −$84.6M | — | −$119.7M | −$105.3M |
| Capital expenditure | $293.0K | $114.0K | $86.0K | $42.0K | $127.0K | — | $23.0K | $1.31M |
| Free cash flow | −$68.0M | −$73.4M | −$92.7M | −$75.4M | −$84.7M | — | −$119.7M | −$106.6M |
From Viridian Therapeutics Ors Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Viridian Therapeutics Ors Inc in our feed yet.